「Immune checkpoint inhibitors for patients with pre-existing autoimmune diseases」の関連論文
-
A case of skin rash during oral administration of a novel androgen receptor inhibitor, darolutamide
-
Lenvatinib-induced severe generalized erythematous rash in a patient with hepatocellular carcinoma
-
The fruits of CD40 research in basic and clinical medicine will soon be harvested
-
Morphea in a Crohn's disease patient undergoing ustekinumab treatment
-
A never-ending FLT3 story
-
Occurrence of cholangiocarcinoma, three years after negative seroconversion of anti-TIF1γ antibody, in a dermatomyositis patient
-
A case of systemic lupus erythematosus/systemic sclerosis overlap syndrome successfully treated with belimumab
-
Effective use of memantine for catatonia in major depressive disorder after failure of electroconvulsive therapy: A case report
-
Clinical response in the haustra-like folds observed during peroral cholangioscopy following steroid therapy for immune checkpoint inhibitor-induced cholangitis.
-
Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab
-
Response to Letter to the Editor: "Acute Bacterial Epiglottitis and COVID-induced Angioedema of the Larynx Are Possible Differential Diagnoses"
-
Squamous Cell Carcinoma at the Site of Cutaneous Lymphoid Hyperplasia
-
Successful treatment of tetanus with magnesium in a dialysis patient
-
Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer
-
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors
-
Comment to our article; Effects of varicocelectomy on testis volume and semen parameters in adolescents: a randomized prospective study
-
Paraneoplastic Pemphigus Mimicking Toxic Epidermal Necrolysis Associated with Follicular Lymphoma: Possible Pathological Role of CD8 T Cells.
-
Autoantibodies against the plakin family proteins as a novel marker for chronic graft-versus-host disease of the lung
-
Increased expression of programmed cell death ligand 1 and galectin 9 in transplant recipients who achieved tolerance after immunosuppression withdrawal
-
Successful treatment with i.v. immunoglobulin and rituximab for bronchiolitis obliterans associated with paraneoplastic pemphigus
-
Long-term risk of cancer development among anti-Th/To antibody–positive systemic sclerosis patients: comment on the article by Mecoli et al
-
MYC Upregulation Is a Useful Biomarker for Preoperative Neoadjuvant Chemotherapy Combined With Anti-EGFR in Liver Metastasis from Colorectal Cancer
-
Recurrent palmoplantar pustulosis at the site of insertion of therapeutic titanium
-
Extensive multiple organ involvement in VEXAS syndrome
-
Clinical and serological features of dermatomyositis and systemic lupus erythematosus patients with autoantibodies to ADAR1
-
Cutaneous T-cell-attracting chemokine as a novel biomarker for predicting prognosis of idiopathic pulmonary fibrosis: a prospective observational study
-
Spontaneous regression of hidroacanthoma simplex after skin biopsy
-
PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma
-
Severe neurodevelopmental disorder caused by an MEF2C nonsense mutation
-
Koebner phenomenon seen in a case of drug-induced granular C3 dermatosis
-
Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease
-
Association of Local Intrapulmonary Production of Antibodies Specific to Donor Major Histocompatibility Complex Class I With the Progression of Chronic Rejection of Lung Allografts
-
A systemic form chronic active Epstein-Barr virus infection diagnosed from erythema nodosum-like skin lesions
-
Correlation of Antidepressant Use and Symptom Time Period in Dream Enactment Behaviors
-
Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease
-
Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease
-
In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy
-
Systemic therapy for salivary gland malignancy: current status and future perspectives
-
Successful dupilumab treatment for ichthyotic and atopic features of Netherton syndrome
-
Elderly patient with 5q spinal muscular atrophy type 4 markedly improved by Nusinersen
-
Timing of therapeutic interventions against infection-triggered encephalopathy syndrome: a scoping review of the pediatric literature
-
Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease
-
Serum S100 calcium-binding protein A4 as a novel predictive marker of acute exacerbation of interstitial pneumonia after surgery for lung cancer
-
Serum S100 calcium-binding protein A4 as a novel predictive marker of acute exacerbation of interstitial pneumonia after surgery for lung cancer
-
Oropharyngeal pleomorphic adenoma causing complete airway obstruction and cardiopulmonary arrest
-
Concepts of Regeneration for Spinal Diseases in 2021
-
Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer
-
Unique reticular hyperkeratotic eruptions seen in a patient with Darier's disease and attention deficit hyperactivity disorder
-
Multidisciplinary diagnostic approach for fulminant myocarditis related to coronavirus disease 2019 messenger RNA vaccines: a case report
-
Underestimation of Trisomy 18 and 13 Syndromes in Vital Statistics from Inadequate Death Certificates.